Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

ABSTRACT:

Background and purpose

In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin. However, concerns exist about potential worse outcomes in dabigatran users if bleeding occurs, given the lack of approved reversal agents. Thus, we examined in-hospital mortality in AF patients with ICB being treated with dabigatran versus warfarin in a real-world population in the United States.

Methods

We analyzed healthcare utilization claims in the Truven Health Marketscan Research Databases. The study sample included patients with AF admitted to a hospital with a primary diagnosis of ICB. Information on medications, inpatient, and outpatient diagnoses was obtained from

SUBMITTER: Alonso A 

PROVIDER: S-EPMC4116615 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature